Menora Therapeutics is a clinical-stage biopharmaceutical company that develops novel drug candidates for serious rare and orphan diseases through a licensing and collaboration model rather than in-house research. The company's primary focus is ALXN1840, a tetrathiomolybdate compound licensed from AstraZeneca targeting Wilson disease, a rare genetic copper metabolism disorder, which has received orphan drug and fast-track FDA designations. Menora outsources preclinical studies, clinical trials, and manufacturing to contract research organizations and manufacturers, and generates revenue potential through eventual product sales and licensing partnerships upon successful clinical development and regulatory approval.